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Abstract
Background: Continuous high global tuberculosis (TB) mortality rates and variable vaccine efficacy of Mycobacterium bovis
Bacille Calmette-Gue ´rin (BCG) motivate the search for better vaccine regimes. Relevant models are required to downselect
the most promising vaccines entering clinical efficacy testing and to identify correlates of protection.
Methods and Findings: Here, we evaluated immunogenicity and protection against Mycobacterium tuberculosis in rhesus
monkeys with two novel strategies: BCG boosted by modified vaccinia virus Ankara expressing antigen 85A (MVA.85A), and
attenuated M. tuberculosis with a disrupted phoP gene (SO2) as a single-dose vaccine. Both strategies were well tolerated,
and immunogenic as evidenced by induction of specific IFNc responses. Antigen 85A-specific IFNc secretion was specifically
increased by MVA.85A boosting. Importantly, both MVA.85A and SO2 treatment significantly reduced pathology and chest
X-ray scores upon infectious challenge with M. tuberculosis Erdman strain. MVA.85A and SO2 treatment also showed
reduced average lung bacterial counts (1.0 and 1.2 log respectively, compared with 0.4 log for BCG) and significant
protective effect by reduction in C-reactive protein levels, body weight loss, and decrease of erythrocyte-associated
hematologic parameters (MCV, MCH, Hb, Ht) as markers of inflammatory infection, all relative to non-vaccinated controls.
Lymphocyte stimulation revealed Ag85A-induced IFNc levels post-infection as the strongest immunocorrelate for
protection (spearman’s rho: 20.60).
Conclusions: Both the BCG/MVA.85A prime-boost regime and the novel live attenuated, phoP deficient TB vaccine
candidate SO2 showed significant protective efficacy by various parameters in rhesus macaques. Considering the
phylogenetic relationship between macaque and man and the similarity in manifestations of TB disease, these data support
further development of these primary and combination TB vaccine candidates.
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Introduction
TB is an ancient infectious disease still afflicting mankind by
causing mortality of over a 1.5 million deaths per year [1].
Increasing incidence of multi- and extensively drug resistant M.
tuberculosis strains and co-infection with HIV make the situation
worse. After several decades BCG (Bacille Calmette-Gue ´rin), that is
derived as an attenuated strain from Mycobacterium bovis, still is the
only available TB vaccine today. However, BCG displays variable
efficacy and poorly protects from the lung disease becoming mostly
manifest during adulthood [2]. New and better therapies, including
cost effective vaccination, are required to effectively fight TB.
Now, vaccines for use in combination with BCG and live
vaccines to replace BCG are both being sought [3–5]. Recently,
live recombinant Modified Vaccinia virus Ankara (MVA)
expressing mycobacterial antigen 85A (MVA.85A) has shown
protection when administered following BCG vaccination in small
vertebrate models [6–8]. It enhances vaccine and naturally primed
responses in humans and is currently undergoing Phase 2 clinical
evaluation [9–13]. An alternative approach is to rationally design
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5264novel live attenuated M. tuberculosis. Here we use a novel vaccine
candidate, SO2, constructed by disrupting the transcription
regulator gene phoP implicated in M. tuberculosis virulence [14].
SO2 was recently shown to induce protection beyond the level of
BCG in mouse and guinea pig models [8,15,16].
Non-human primates as phylogenetically the closest relatives to
man and naturally susceptible to M. tuberculosis infection comprise
a valuable model for investigating aspects of TB disease and
protection [17–20], and for preclinical TB vaccine testing [21–24].
They can be considered to hold strong predictive validity and
expected to support vital downselection of the most promising
vaccines entering clinical efficacy testing.
Here, we used rhesus macacques (Macaca mulatta) as non-human
primate hosts in a fixed-endpoint protocol including BCG-
vaccinated and non-vaccinated animals as control groups, to
demonstrate immunogenicity and protective efficacy of the
MVA.85A booster and SO2 live attenuated vaccine candidates
against M. tuberculosis challenge. Ex vivo lymphocyte stimulation
testing with specific antigens and recording IFNc secretion as a key
mediator of protective immunity was performed to correlate
specific responses to protection. The phylogenetically related
rhesus macaque model, including correlates of TB disease, is
further defined and holds potential for future identification of
better endpoints for clinical efficacy testing.
Results
Vaccination, infectious challenge and treatment group
characteristics
Vaccine treatments, dose and route of injection, and treatment
group characteristics, number of animals (n), age and body weight,
are summarised in Table 1. A schematic diagram representing the
experiment is depicted in Figure 1. In brief, eighteen weeks after
primaryvaccination,animalswerechallengedinasingle,randomised
session by intratracheal instillation of 1000 colony forming units
(CFU) of M. tuberculosis Erdman strain. The study plan accommo-
dated a fixed endpoint with pathologic examination after euthanasia
(by random sampling) at week 16/17 post-infection. Random
stratification of animals over the four treatment groups warranted
homogeneous distribution of body weight and age without significant
differencesbetweenthegroupsatthestartoftheexperiment(Table1).
Elevated antigen-specific IFNc levels upon in vitro
stimulation after vaccination showing effectivity of
vaccination
Following vaccination no clinically significant changes in
behaviour, weight or parameters of hematology and clinical
chemistry were evident in any group (data not shown). Mild
swelling and redness occurred at the MVA injection site with self-
limiting vesicle and crust formation not requiring medical attention
andreminiscentofobservationsinhumanMVAvaccination[7].All
vaccinated groups, but not non-vaccinated controls, showed
increased IFNc secretion against M. tuberculosis purified protein
derivative (PPD); responses were maximal at week 9 post-primary
immunisation and highest in the SO2 group (Figure 2A and 2B).
Antigen 85A-specific IFNc secretion increased after booster
immunisation with MVA.85A only (Figure 2C and 2D).
TB-associated pathology and lesion scores upon autopsy
revealed protective vaccine effects
All but three animals reached fixed protocol endpoint (week 16/
17). Two non-vaccinated controls reached humane endpoint at
week 12 post-infection due to sustained weight loss, and one BCG-
vaccinee was withdrawn at week 14 post-infection after showing
signs of distress. According to study plan these humanely culled
animals, like those at fixed endpoint by protocol, underwent full
pathologic examination at autopsy. All three showed active
pulmonary TB and hilar lymph node (LN) involvement. The
two non-vaccinated controls, but not the BCG vaccinee, presented
with extra-pulmonary lesions (see below). Also, upon humane
withdrawal defined clinical parameters (see below) were recorded
to warrant a complete set of data for comprehensive analysis of 24
individuals at time of autopsy as an endpoint.
Upon pathologic examination most severe disease was generally
observed in non-vaccinated controls. At autopsy all these control
animals revealed lesions in their lungs and macroscopic pathologic
findings were consistent with multi-focal to coalescing caseous and
occasional non-necrotic, young nodules (tubercula). Histologically
granulomas were apparent with or without necrotic centres, with
neutrophils, and surrounded by epitheloid macrophages, scattered
multi-nucleated giant cells, infiltrates of lymphocytes and plasma
cells, and a peripheral rim of fibroblasts and collagen fibres. Beside
specific tuberculous granulomatous lesions gross examination also
revealed pulmonary changes including congestion in 6 out of 6
non-vaccinated controls, consolidation in 4 out of 6, pleural
fibrinoid adhesions in 5 out of 6, oedema in 6 out of 6, and areas of
emphysema in 2 out of 6 (Table 2). Hilar lymph nodes (LN) were
grossly affected in all non-vaccinated controls. To evaluate possible
dissemination of infection from the lung, spleen, liver, kidneys,
heart, pancreas and gastrointestinal tract (GIT) were routinely
inspected for gross appearance of lesions. In 4 out of 6 non-
vaccinated controls any such extra-thoracic lesions (involving
spleen, liver, kidney, heart and pancreatic lymph node) were
apparent (Table 2).
Table 1. Treatment groups, dosing, routing and group characteristics.
Treatment mean age mean weight
Treatment Abbreviated Dose Route n years (95%CI
1) kg (95%CI
1)
1 non-vaccinated non-v n.a.* n.a.* 6 8.1 (7.2–8.9) 8.5 (7.2–9.8)
2 BCG vaccinated BCG 5610
5 CFU i.d.
# 6 7.8 (7.1–8.4) 9.0 (6.8–11.1)
3 BCG primed and B(CG)/MVA 5610
5 CFU i.d.
# 6 8.0 (6.9–9.1) 9.1 (7.3–10.9)
MVA.85A boosted 5610
8 PFU i.d.
#
4 SO2 vaccinated SO2 5610
5 CFU i.d.
# 6 8.3 (7.9–8.9) 8.6 (6.9–10.2)
*n.a.: does not apply.
#i.d.: intradermally.
1CI: confidence interval.
doi:10.1371/journal.pone.0005264.t001
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animals; one had no signs of gross lung lesions (Table 2). With
exception of one, all BCG controls showed hilar lymph node (LN)
involvement, and dissemination outside the thorax was observed in
1 of 6 BCG only animals and limited to the spleen.
BCG/MVA.85A vaccinated animals developed less severe
disease and presented with fewer lesions than BCG only and
naive controls: 3 out of 6 had no macroscopic pulmonary TB
lesions; 2 of 6 showed no hilar LN involvement; only 1 of 6
displayed extra-thoracic dissemination to liver and spleen (Table 2).
Microscopically, TB lesions were more fibrosed and confined,
suggestive of healing (not shown).
Of the SO2 vaccinees 5 out of 6 showed macroscopic
pulmonary lesions. However, disease was reduced compared to
non-vaccinated controls, with less animals showing congestion,
consolidation, fibrinous pleuritis or oedema (Table 2). Hilar LN
were prominently involved in all SO2 animals; disseminated
lesions apparent in only 2 of 6 involving spleen and liver (Table 2).
Using a predefined arbitrary gross pathology (PA) scoring
system for TB-associated lesions at autopsy, partial protection
against challenge was demonstrated in all vaccine groups.
Summed PA scores were 142, 63.5, 39 and 61 for non-vaccinated,
BCG, BCG/MVA and SO2 groups, respectively (Table 2). As
depicted in Figure 3A and 3C similar trends of reduced pathology
after vaccination were observed for both lung PA and dissemi-
nated disease by extra-thoracic PA, respectively. The reduction in
macroscopic lung PA was statistically signficant (p,0.05) for both
BCG/MVA and SO2 treatment and approached significance
(0.1.p.0.05) for BCG alone. Hilar LN pathology was particu-
larly reduced after BCG/MVA vaccination (Figure 3B). Hilar LN
involvement and extra-thoracic PA showed relatively weak
correlation with gross lung PA at autopsy as calculated by non-
parametric Spearman’s rho (Rs) (Figure 4C and 4D, respectively).
Chest X-rays post-infection indicated reduction of lung
pathology or delay of disease kinetics after vaccination
As a means of non-invasive diagnostic assessment of TB-
associated lung pathology we took conventional anterior-posterior
chest X-rays (CXR) of the animals along the post-infection phase.
A pre-defined arbitrary scoring algorithm was applied to obtain a
semi-quantitative score of individual chest X-ray results at 8 and
12 weeks post-infection and immediately prior to autopsy. CXR at
autopsy timepoints (Figure 3E), like gross lung PA scores
(Figure 3A), revealed reduced median values for all vaccine
groups in comparison to non-vaccinated controls. In comparison
to non-vaccinated controls at endpoint (autopsy) BCG/MVA
prime-boost treatment, but not SO2, revealed a median CXR
score that was significantly lower, while CXR score after BCG
control vaccination approached significance. The correlation
between CXR results at autopsy and gross lung PA scores as
calculated by non-parametric Spearman’s rho (Rs) was strong
(Rs=0.75) and highly significant (p,0.0001) (Figure 4A).
Group averages of CXR scoresin time are displayed in Figure 3F
and reflect differential dynamics of lung disease between the
treatment groups. While non-vaccinated controls showed progres-
siveincreaseinCXRscoresover theinfection phase,both BCGand
BCG/MVA showed decreasing CXR signals from week 8 post-
infection onward. The SO2 vaccine group showed reduced CXR
scores at weeks 8 and 12 post-infection, significantly lower than the
non-vaccinated, but not BCG alone control group (Figure 3F).
However, by the time of fixed endpoint of this study (week 16/17
post-infection by protocol) and unlike the reduction of PA and
bacterial loads in the lung, this group displayed increased CXR
scores similar to the level of those in non-vaccinated and BCG-
primed animals at week 8 post-infection (Figure 3F). Together,
CXR results for SO2 vaccination suggest a remarkable delay in the
onset of TB lung disease after high-dose infectious challenge.
Figure 1. Experimental plan. A schematic diagram illustrating the timelines of vaccination (priming at week 0, boosting at week 9 for group 3
only), infectious challenge, immune monitoring, chest X-ray recording and fixed endpoint/autopsies by study protocol all relative to the 18 weeks
immunisation phase or the 17/18 weeks challenge phase.
doi:10.1371/journal.pone.0005264.g001
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vaccination
A possible reduction in bacterial burden by counting colony
forming units (CFU) from tissue is a measure for protective efficacy
often assessed in experimental vaccine testing. To this end, we
collected and minced the whole lung (after pathologic evaluation
and histologic sampling) and further homogenised a random
sample for CFU determination. The results are depicted as
10logCFU per gram of lung tissue in Figure 3D. In comparison to
non-vaccinated controls BCG vaccination revealed an average
reduction in bacterial load of 0.43 log, whereas BCG/MVA
reduced CFU by 1.0 log and SO2 by 1.2 log. Bacterial load and
lung PA correlated relatively weakly but significantly (Figure 4B).
Protective vaccine effects by clinical measures of wasting
and inflammation
Progressive tuberculosis in man is hallmarked by wasting disease
and inflammation. Therefore, in this monkey experiment we
measured changes in total body weight and several markers of
Figure 2. Mycobacterium-specific IFNc secretion post-vaccination. Both the SO2 primary and the MVA.85A booster vaccine are
immunogenic in rhesus macaques. Antigen-specific IFNc secretion was measured after 3 days of in vitro stimulation of fresh peripheral blood
lymphocytes along the vaccination phase. PPD-specific IFNc secretion is depicted as group mean responses (+standard error) in time (A), and as
individual responses with medians at the peak of the mean group response (B). Similarly, results upon stimulation with recombinant Ag85A are
displayed as group means (+standard error) in time (C), and as individual responses (with medians) at peak (D), respectively. Colouring of group
medians (panels A and C) is representing non-vaccinated controls in blue, BCG only in green, BCG/MVA.85A in magenta, and SO2 vaccination in red;
group colouring is maintained throughout the paper for comparibility of data. Dot plots representing individual animals (panels B and D) are
consistently coloured as follows: animals per treatment group were ranked from highest to lowest total gross pathology score (sum of lung, hilar LN
and extra-thoracic scores) and then assigned the colours: blue, green, magenta, red, brown, black, respectively; individual colouring is maintained
throughout for comparability. P-values are relative to non-vaccinated control treatment and represented under the x-axis by symbols as follows: &
for 0.1.p$0.05, w for 0.05.p$0.01, ww for 0.01.p$0.001.
doi:10.1371/journal.pone.0005264.g002
Table 2. Summary of frequencies of TB-associated pathologic
manifestations and total lesion scores per treatment group.
Treatment Group: non-v BCG BCG/MVA SO2
lung lesions (n/N) 6/6 5/6 3/6 5/6
congestion (n/N) 6/6 5/6 2/6 4/6
consolidation (n/N) 4/6 3/6 1/6 1/6
fibrinous pleuritis (n/N) 5/6 3/6 1/6 3/6
oedema (n/N) 6/6 5/6 1/6 3/6
emphysema (n/N) 2/6 3/6 1/6 1/6
hilar LN involvement (n/N) 6/6 5/6 4/6 6/6
extra-thoracic lesions (n/N) 4/6 1/6 1/6 2/6
sum of total PA lesion scores
(arbitrary units)
142.0 63.5 39.0 61.0
doi:10.1371/journal.pone.0005264.t002
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Wasting was reflected in the non-vaccinated controls by a (relative)
loss of weight from pre-infection to the autopsy timepoint
(Figure 5A). This weight loss was reversed by vaccination, and
statistically significant improvement in comparison to non-
vaccinated, but not to BCG controls was obtained for both
BCG/MVA and SO2 (Figure 5A).
To assess systemic inflammation, levels of C-reactive protein
(CRP) were measured in fresh serum samples along the infection
phase and the absolute change in individual CRP levels from pre-
infection to the autopsy timepoint is depicted in Figure 5B. While
all animals typically displayed low CRP levels within normal
ranges prior to infection (not shown), at autopsy the non-
vaccinated control group showed systemic inflammation by a
marked increase in CRP. Vaccination suppressed this inflamma-
tory response and most significantly in the BCG/MVA group in
which 5 out of 6 revealed no increase in CRP at all (Figure 5B).
Concordantly, erythrocyte-associated hematologic markers
reflecting systemic inflammation such as decreasing values of
mean corpuscular volume (MCV) and mean corpuscular hemo-
Figure 3. Evaluation of gross pathology, radiology and bacterial loads upon infectious challenge. Individual scores per treatment group
and group median values are plotted for macroscopic lung pathology (PA) (A), hilar LN involvement (B), extra-thoracic PA (C), bacterial burden in the
lung (D), and chest X-ray (CXR) scores at autopsy (E). Kinetics of TB disease are reflected by mean CXR scores (+standard error of the mean) per
treatment group in time (F). BCG/MVA shows protection by significantly reduced lung lesion scores and CXR scores at autopsy compared to non-
vaccinated controls, and by reduced hilar LN involvement and CFU in the lung (not significant). SO2 in comparison to non-vaccinated controls shows
significant protection by reduced lung lesion scores and delayed kinetics of TB by CXR in time, and by reduced CFU in the lung (not significant). For
legends of colouring and symbols see legend to Figure 2. For BCG/MVA treatment CXR at autopsy n=5; one recording censored due to technical
error.
doi:10.1371/journal.pone.0005264.g003
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with lung PA. Loss of total body weight (wasting), and C-reactive protein (CRP) levels and decreasing mean corpuscular volume (MCV) and mean
corpuscular hemoglobin (MCH) as measures of systemic inflammation, are highly significant correlates of disease in this high dose challenge model
for TB vaccine evaluation. Parameters are plotted per individual (with colouring as indicated in the legend to Figure 2 on group colouring) against
lung PA for CXR scores at autopsy (A), CFU counts from lung homogenates (B), hilar LN involvement (C), disseminated extra-thoracic lesions (D), and
against total pathology (the sum of lung, hilar LN and extra-thoracic PA scores) for relative change in body weight (E), change in CRP (F), change in
MCV (G) and in MCH (H). Spearman’s rho (Rs) as correlation factor and p-value are indicated. (AU for arbitrary units.)
doi:10.1371/journal.pone.0005264.g004
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hematocrit (Ht) and hemoglobin (Hb) levels (not shown),
corroborated the finding of systemic inflammation post-infection
in the non-vaccinated control group. Again, vaccination sup-
pressed this inflammatory response (Figure 5C and 5D). Like with
CRP, live attenuated SO2 gave similar results as BCG for change
in MCV and MCH. For SO2 vaccinees, but not for BCG, group
medians of change in CRP and MCV were significantly different
from those in non-vaccinated controls (Figure 5B and 5C), or
approaching significance as for MCH (Figure 5D). MVA.85A
vaccinated animals, except for one, showed no relevant decrease in
MCV or MCH at all, and group medians were significantly
different from the non-vaccinated, but not the BCG alone, control
group.
These clinical measures of weight loss and change in CRP,
MCV and MCH along the infection phase all displayed a strong
and highly significant (non-parametric) correlation with total gross
pathology (the sum of lung, hilar LN and extra-thoracic lesion
scores) as depicted in Figure 4E, 4F, 4G and 4H, respectively.
Antigen-specific IFNc release post-infection and
correlation of IFNc secretory responses with pathology
Specific immune responses in the post-infection phase were
monitored by measuring IFNc secretion levels from fresh PBMC
samples stimulated in vitro with PPD, recombinant Ag85A or
ESAT6/CFP10 fusion protein. PPD- and ESAT6/CFP10 stimu-
lation revealed highest IFNc secretion in non-vaccinated controls
in general at 6–8 weeks post-infection (Figure 6A and 6B, and 6E
and 6F, respectively). In vaccine groups generally these responses
were lower than in the non-vaccinated control group. In contrast,
post-infection Ag85A specific IFNc responses were relatively low
(in the sub-nanogram range), and on average lower in non-
vaccinated controls than in BCG/MVA and SO2 vaccine groups
particularly (Fig 6C and 6D).
For both post-vaccination (pre-infection) and post-infection time-
points coefficients of correlation between individual maximal antigen
specfic IFNc levels and total PA lesion scores were calculated.
Maximal PPD specific IFNc levels post-vaccination (Figures 7A), but
not post-infection (Figures 7B), showed a significant and inverse
correlation with total PA (Rs=20.49, p=0.0140). Contrarily,
maximal IFNc release upon Ag85A stimulation post-infection
(Figure 7D), but not post-vaccination (Figure 7C), correlated
significantly with disease by total PA lesion score (Rs=20.60,
p=0.0018). ESAT6/CFP10 specific maximal IFNc secretion, which
was monitored in the post-infection phase only, did not correlate
significantly with total PA at autopsy (Figure 7E).
Discussion
In the present study both a viral vaccine regime using
recombinant MVA expressing Ag85A, subsequent to standard
BCG primary vaccination, as well as a novel live attenuated M.
tuberculosis strain SO2 used as a prime and only vaccine, showed
induction of specific immunity and statistically significant
protective effects from TB disease as observed in non-vaccinated
control rhesus monkeys. Both experimental vaccines appeared safe
and showed no relevant clinical adversity under the observational
conditions of the experiment.
Figure 5. Evaluation of clinical measures along the infection phase. The BCG/MVA.85A regime and SO2 vaccination in comparison to non-
vaccinated controls show significant protection from TB-associated wasting disease and systemic inflammation. Individual scores and group medians
are plotted for relative change in body weight from start to end of the infection phase (A), change in C-reactive protein (CRP) levels (B), in mean
corpuscular volume (MCV) (C), and in mean corpuscular hemoglobin (MCH) (D). For legends of colouring and symbols see legend to Figure 2.
doi:10.1371/journal.pone.0005264.g005
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tuberculosis Erdman strain intratracheally triggered acute disease in
the non-vaccinated control rhesus monkeys. This active TB disease
was characterised by serious necrotic to coalescing lesions in the
lungs and often involved other organs indicating disseminated
disease. In accordance with lung PA, these non-vaccinated
controls presented with gradually increasing lung lesion burden
by longitudinal chest X-ray diagnosis. As in active human TB,
these non-vaccinated rhesus macaques displayed wasting disease
by loss of total body weight along the infection. Moreover,
systemic inflammation as measured by increased C-reactive
protein levels and by decreasing values for the erythrocyte-
associated measures mean corpuscular volume and mean
corpuscular hemoglobin (and the related hematocrit and hemo-
globin concentration) was apparent.
Significant protective efficacy in comparison to non-vaccinated
controls could be assigned by using non-parametric statistical
evaluation (p,0.05) for both BCG/MVA and SO2 and by using 6
outbred animals per treatment group only. Protection was
specifically reflected by significantly reduced gross lung lesion
scores, CXR scores (but at varying timepoints for the different
experimental regimes, see also below), wasting, and systemic
Figure 6. Mycobacterium-specific IFNc secretion post-infection. Both PPD and ESAT6-CFP10 fusion protein, but not Ag85A, induce relatively
high levels of IFNc from in vitro stimulated fresh PBMC after infectious challenge with M. tuberculosis. Treatment group means (+standard errors) are
plotted in time for PPD (A), Ag85A (C) and ESAT6/CFP10 fusion protein (E), and as individual responses (with group medians) at the peak of the mean
response as indicated (B, D and F, respectively). For legends of colouring and symbols see legend to Figure 2.
doi:10.1371/journal.pone.0005264.g006
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values. Average CFU counts from the lungs were reduced by
about 1 log compared to non-vaccinated controls, but not
significant. Also, the BCG only control group, although not
significant (p.0.05), showed protective effects by these parameters
over non-vaccinated controls. However, under these conditions
and using group sizes of 6, significant improvement beyond BCG
could not be detected, neither with the MVA.85A vaccination nor
the SO2 prime regime.
Generally, new TB vaccine strategies initially undergo evalua-
tion to show protective efficacy in mouse and guinea pig models.
One of those, the MVA.85A booster vaccine, to the best of our
knowledge, is currently the most advanced in clinical safety trials
[3,11]. Here BCG/MVA demonstrates protective efficacy in non-
human primates, supporting evaluation of the strategy in costly
human efficacy trials. Improvement beyond BCG is suggested by
further reduction of lung PA, hilar LN involvement, lung CFU,
wasting and CRP levels, and more stable levels of MCV and
MCH by study endpoint.
Data following SO2 vaccination of rhesus monkeys furthers
proof of principle and extends the notion of this novel phoP
deficient M. tuberculosis as a safe, immunogenic and protective
vaccine candidate to the primate host. In comparison to BCG, this
primary vaccine candidate showed similar protection by similar
Figure 7. Immune correlations of disease. Maximal PPD-specific IFNc levels post-vaccination and maximal Ag85A-specific IFNc post-infection
show significant inverse correlations with TB disease by total gross lesion PA scores. Maximal antigen-specific IFNc response levels are plotted per
individual against total pathology scores (with colouring as indicated in the legend to figure 2 on group colouring) and post-vaccination and post-
infection for PPD (A and B, respectively) and Ag85A (C and D, respectively), and for ESAT6-CFP10 fusion protein post-infection only (E).
doi:10.1371/journal.pone.0005264.g007
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and of systemic inflammation. While BCG on average reduced
CFU in the lungs by 0.4 log, CFU were down by 1.2 log in the
SO2 treated. Longitudinal CXR scores were reduced 8 and 12
weeks post-infection as compared to BCG and non-vaccinated
controls. By the end of the study at week 16, however, CXR scores
in SO2 were similar to those observed in the other groups at week
8. Together with the relatively strong hilar lymph node
involvement in the SO2 vaccinees, this suggests that these animals
only developed active TB by the endpoint by protocol to a level
observed for BCG and non-vaccinated controls at week 8 already.
While the data here indicate that SO2 shows a remarkable delay
in the kinetics of TB in the face of a high dose challenge with 1000
CFU intratracheally and relative to BCG treated animals, further
studies are needed to investigate whether disease would deteriorate
or whether it would go ‘in remission’ like suggested by the CXR
dynamics for the BCG vaccinated macaques in this study from
week 8 post-infection onward.
Targeted disruption of phoP reduces ESAT6 secretion and
expression of lipids implicated in virulence and immune
modulation, retains immunodominant M. tuberculosis products
missing from BCG, and provides more attenuation than BCG in
SCID mice [15,25–28]. Lung homogenates plated on selective
medium did not reveal SO2 persistence in vaccinated animals,
corroborating the SO2 safety profile (not shown). With regard to
safety the next development step for SO2 requires the creation of
an additional, independent mutation [29,30]. Together, this M.
tuberculosis derived live phoP gene knock-out SO2 vaccine candidate
is the first of its kind, different from M. bovis derived BCG and
rationally engineered to attenuation, that holds potential to protect
the primate host. Generally, live mycobacterial vaccines may hold
promise to replace and improve upon BCG as a single-dose
primary vaccine in the future.
We have previously reported failure of BCG to protect against M.
tuberculosis Erdman challenge in rhesus macaques, in contrast to
findings here [18]. This apparent paradox is subject to ongoing
investigation, this indicating animal origin, consequent to geograph-
ically restricted genetic/environmental factors (including pre-expo-
sure),maysignificantlyaffectlivevaccineoutcomes.However,disease
kinetics in rhesus macaques, as corroborated by chest X-ray results
here, indicate that 8/9 weeks post-infection (the fixed endpoint forthe
former study) is too early to reveal protective effects in BCG
vaccinated rhesus macaques. The delayed onset of lung pathology in
SO2 vaccinated animals further suggests that endpoints beyond the
16 weeks post-infection used here are warranted.
Immune monitoring post-infection by using PBMC and in vitro
stimulation with PPD or ESAT6-CFP10 fusion protein revealed
reduced IFNc release from vaccine groups as compared to non-
vaccinated controls. Speculatively, this reduction of antigen-
specific responsiveness suggests that vaccination may lead to
reduced antigen-specific peripheral immune activity due to
protection (i.e. reduced mycobacterial load and hence reduced
immune stimulation), to regulatory responses suppressing IFNc
release, and/or to specific homing of antigen-specific lymphocytes
to infected tissues post-infection in the vaccinated. Proof for any of
these explanations and their possible relative contribution will
require further in-depth investigations. In agreement with the
concept of inducing a protective IFNc positive cellular immune
response by vaccination, maximal PPD-specific IFNc levels post-
vaccination showed an inverse and significant correlation with
total gross pathology. Post-infection, however, this association by
non-parametric evaluation by Spearman’s rho could not be
identified. In contrast to PPD or ESAT6/CFP10 induced
responses post-infection, there is no sign of reduced Ag85A
specific IFNc in the vaccinated versus non-vaccinated groups. In
addition, maximal IFNc release levels upon Ag85A stimulation
post-infection correlate well and inversely with disease outcome by
gross pathology scoring. While the MVA.85A vaccine is
specifically designed to enhance that response, apparently also
SO2 as a primary vaccine allows for the detection of elevated
Ag85A-specific IFNc in the early post-infection phase. Thus,
Ag85A-specific IFNc may represent an interesting marker for
future vaccine evaluations.
We demonstrate here the potential for BCG/MVA and SO2
vaccine strategies to protect phylogenetically related, naturally
susceptible primates, providing support towards clinical assessment
of these strategies. This study corroborates and extends the value
of non-human primate TB models by further defining and
correlating pathologic, radiologic, bacteriologic, clinical and
hematologic read-outs, which improves vaccine selection prior to
expensive and time-consuming clinical Phase IIb/III efficacy trials
in high transmission areas. Elucidation of rhesus macaque and M.
tuberculosis genomes [31,32] provides opportunities to further
identify mechanisms and (surrogate) markers of protection to
accelerate TB vaccine development.
Materials and Methods
Ethics Statement
All animals in this study were captive bred for research
purposes. BPRC housing and animal care procedures are in
compliance with Dutch law on animal experiments, European
directive 86/609/EEC, and with the ‘‘Standard for Humane Care
and Use of Laboratory Animals by Foreign Institutions’’,
identification number A5539-01, provided by the Department of
Health and Human Services of the US National Institutes of
Health (NIH). The local independent ethical committee, consti-
tuted according to Dutch law on animal experiments, approved
the study protocol prior to start of the experiment. Humane
endpoints were pre-defined in this protocol and applied as a
measure of reduction of discomfort.
Animals
Healthy adult male rhesus monkeys (Macaca mulatta) were
selected and randomly stratified on basis of age and body weight
over 4 groups of 6 animals each. Monkeys were selected to be
naive to prior mycobacterial exposure on the basis of a negative
Mantoux skin reaction using Old Tuberculin (Statens Serum
Institute (SSI), Copenhagen), a negative result in the PrimagamH
kit measuring M.bovis/M.avium PPD specific IFNc release in whole
blood cells (Biocor Animal Health, Omaha, Nebraska, USA), and
clean chest X-rays lacking any signs of TB (see below).
Animal handling
Animal handlings were performed after sedation (ketamine,
10 mg/kg). Heparinised blood for immune monitoring, EDTA
blood for standard hematology, and serum for standard clinical
chemistry were collected by venipuncture. Animal condition was
monitored by daily observation and body weights recorded at all
bleeding time points. Animals were challenged by intratracheal
instillation of 1000 CFU of M. tuberculosis Erdman strain (kindly
provided by P. Andersen c.s. from SSI, Copenhagen; cultured,
aliquoted and stored by D. van Soolingen c.s. at RIVM,
Bilthoven).
Vaccines
M.bovis BCG (SSI, Copenhagen, Denmark; batch 10307D) was
prepared as prescribed by the manufacturer. MVA.85A and SO2
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stock solution in Sauton diluent prior to vaccination. All vaccines
were applied by intradermal injection in the upper arm (booster
vaccination in the opposite arm; timing and dosing as indicated).
Autopsy and pathologic evaluation
For logistical reasons euthanasia by intravenous injection of
sodium pentobarbital (EthasolH, AST Farma, Oudewater) oc-
curred at fixed time points on group sampling basis on 5 separate
days (maximal interval of 8 days). At autopsy, gross pathology (PA)
was scored while blinded for treatment according to an algorithm
predefined by S. Reed, J.A. Flynn, and J.A.M. Langermans
(unpublished). Lymph node involvement was scored as 1 (gross
appearance of 1 lesion), 2 (several separate foci/necrotic areas) or
3 (extensive caseous necrosis). Five lung lobes were distincted and,
like other organs, were scored as 1 (one gross lesion of ,10 mm in
diameter), 2 (two to five lesions ,10 mm), 3 (more than five lesions
of ,10 mm or one lesion of .10 mm), 4 (more than one lesion of
.10 mm), 5 (coalescing lesions); the total lung score was
maximally 25. Histopathologic examination used formalin fixed
and paraffin-embedded tissues according to regular procedures.
Chest X-rays
CXR were obtained by exposure (76–80 Volt, 3 mAs) and using
phosphor imaging plates, a CR2340 scanner, and Vision software
(Vetray GmbH, Pfaffenhofen, Germany) for recording and
reading. Readings were interpreted clinically and scored, while
blinded to treatment, according to an algorithm adapted by
K.v.K. from N. Mlika-Cabanne et al. [33]. Briefly, a semi-
quantitative evaluation yields scores for each upper, middle and
lower regions of the right and left lung on predominant infiltrates
of 1 (small nodules), 2 (patchy appearance), 3 (consolidation).
Besides, cavitation, pleural effusion and lymphadenopathy are
scored (0, absent, 1 present) when it applies.
Bacteriology
After collecting small representative samples for histopathology
and cryopreservation, whole lungs were minced and a represen-
tative aliquot homogenised (PRO-200 homogenator; PRO
Scientific, Oxford, CT). Diluted lung homogenates were plated
on Middlebrook 7H10 medium plus OADC supplements and
cycloheximid (100 mg/ml), (Tritium Microbiologie BV., Veldho-
ven, the Netherlands) to determine colony forming units (CFU) as
a measure of bacterial load.
Immune assays
Peripheral blood mononuclear cells (PBMC) were isolated
freshly by density gradient centrifugation and immediately used in
lymphocyte stimulation tests. Antigen-specific IFNc secretion was
assessed on duplicates in a non-human primate specific sandwich
ELISA (U-CyTech, Utrecht) on pooled supernatants of triplicates
of 2610
5 PBMC (per well) cultured for 3 days with and without
antigen in RPMI 1640 culture medium supplemented with 10%
(w/v) foetal calf serum and penicillin/streptomycin (Invitrogen;
Leek, the Netherlands). Protein purified derivative of M. tuberculosis
(RT49) (SSI; Copenhagen, Denmark), recombinant Ag85A and
ESAT6/CFP10 fusion proteins were used at a final concentration
of 10 mg/ml. Concanavalin A (Sigma, St. Louis) was used at 5 mg/
ml as a positive control stimulus.
Clinical assays
Standard parameters were determined for hematology (Sysmex
XT 2000iV platform; Goffin Meyvis, Etten-Leur, the Netherlands)
and clinical chemistry (Cobas Integra 400; Roche Diagnostics,
Basel, Switzerland) on freshly obtained blood samples. C-reactive
serum protein levels were determined using anti-CRP coated latex
particles (Roche Diagnostics).
Statistical analysis
Data were analysed by evaluating individual treatment groups
by two-sided, non-parametric Mann-Whitney rank testing using
Graph Pad PrismH software. Variance (R) between parameters
and the p-values for R were calculated by non-parametric
Spearman’s rho also using Graph Pad PrismH. In general, results
were considered significant for p-values smaller than 0.05, and for
0.1.p$0.05 interpreted as approaching significance.
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